Author
Baddley, John WThompson, George R
Chen, Sharon C -A
White, P Lewis
Johnson, Melissa D
Nguyen, M Hong
Schwartz, Ilan S
Spec, Andrej
Ostrosky-Zeichner, Luis
Jackson, Brendan R
Patterson, Thomas F
Pappas, Peter G
Date
2021-11-16Journal
Open Forum Infectious DiseasesPublisher
Oxford University Press (OUP)Type
Article
Metadata
Show full item recordAbstract
Coronavirus disease 2019 (COVID-19) can become complicated by secondary invasive fungal infections (IFIs), stemming primarily from severe lung damage and immunologic deficits associated with the virus or immunomodulatory therapy. Other risk factors include poorly controlled diabetes, structural lung disease and/or other comorbidities, and fungal colonization. Opportunistic IFI following severe respiratory viral illness has been increasingly recognized, most notably with severe influenza. There have been many reports of fungal infections associated with COVID-19, initially predominated by pulmonary aspergillosis, but with recent emergence of mucormycosis, candidiasis, and endemic mycoses. These infections can be challenging to diagnose and are associated with poor outcomes. The reported incidence of IFI has varied, often related to heterogeneity in patient populations, surveillance protocols, and definitions used for classification of fungal infections. Herein, we review IFI complicating COVID-19 and address knowledge gaps related to epidemiology, diagnosis, and management of COVID-19-associated fungal infections.Sponsors
Centers for Disease Control and PreventionIdentifier to cite or link to this item
http://hdl.handle.net/10713/17341ae974a485f413a2113503eed53cd6c53
10.1093/ofid/ofab510
Scopus Count
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/